JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight
The JAK inhibitors market is expected to witness steady growth, driven by the increasing prevalence of autoimmune and inflammatory diseases, growing adoption of targeted therapies, and the expanding clinical use of JAK inhibitors across multiple indications. Furthermore, the launch of emerging therapies such as Povorcitinib (Incyte), PRT12396 (Prelude Therapeutics/Incyte), BHV-8000 (Biohaven), Modzatinib (ATI-2138; Aclaris Therapeutics), TLL-018 (Highlightll Pharma), and others will further propel the market growth.
LAS VEGAS, Oct. 26, 2026 /PRNewswire/ -- DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Alopecia Areata, Ulcerative Colitis, Crohn's Disease, Myelofibrosis, Polycythemia Vera, GvHD, Vitiligo, Systemic Lupus Erythematosus, Hidradenitis Suppurativa, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging JAK inhibitor drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).
Key Takeaways from the JAK Inhibitors Market Report
Discover the JAK inhibitors classification @ https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-market
Key Factors Driving the JAK Inhibitors Market
Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that the market remains competitive, with established agents benefiting from expanding indications while newer, more selective JAK inhibitors aim to improve efficacy and safety profiles.
JAK Inhibitors Market Analysis
Learn more about the list of JAK inhibitors @ JAK Inhibitor Drugs List
JAK Inhibitors Competitive Landscape
Some of the JAK inhibitor drugs under development include Povorcitinib (Incyte), PRT12396 (Prelude Therapeutics/Incyte), BHV-8000 (Biohaven), Modzatinib (ATI-2138; Aclaris Therapeutics), TLL-018 (Highlightll Pharma), SDC-1801 (Sareum Holdings), AC-201/FXS5626 (Accro Bioscience/Fosun Pharma), Brepocitinib (Priovant Therapeutics/Pfizer), and others.
Incyte's Povorcitinib (INCB054707) is an orally administered, small-molecule inhibitor of JAK1. Its chemical structure was disclosed in the WHO Proposed INN List 126 in January 2022, where it was classified as a Janus kinase inhibitor with anti-inflammatory properties. The drug is also being investigated in Phase III clinical trials for prurigo nodularis and other indications. Currently, povorcitinib is in the preregistration stage for hidradenitis suppurativa.
Aclaris Therapeutics' Modzatinib is an investigational oral covalent inhibitor of interleukin-2-inducible T-cell kinase (ITK) and Janus kinase 3 (JAK3), two important targets involved in immune regulation. ITK inhibitors act on ITK, a non-receptor tyrosine kinase involved in T-cell receptor (TCR) signaling, thereby modulating the development, activation, and effector functions of T cells. As a key signaling kinase downstream of the TCR, ITK regulates the expression of cytokines such as IL-17 and IFN-γ. By simultaneously affecting T-cell receptor signaling, which influences T-cell maturation and activation, and IL-17 production, ITK inhibition may provide effects similar to those of a "small-molecule anti-IL-17" therapy while offering broader immunomodulatory activity.
JAK3 plays a critical role in signaling through the common gamma-chain cytokine receptor and regulates several cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. By targeting both ITK and JAK3, a dual inhibitor such as modzatinib may produce additive or synergistic anti-inflammatory effects, potentially providing therapeutic benefits across a range of autoimmune and inflammatory diseases.
Sareum's TYK2/JAK1 clinical development candidate, SDC-1801, exhibits high selectivity toward TYK2 and JAK1 kinases, particularly compared with the closely related JAK2 and JAK3 kinases. The candidate has demonstrated promising efficacy in preclinical models of psoriasis and rheumatoid arthritis, along with the potential for once-daily oral administration and a favorable early safety profile. Related compounds, including SAR-20347, have also shown encouraging activity in models of inflammatory bowel disease and systemic lupus erythematosus (SLE). These findings supported the advancement of SDC-1801 into human clinical development, with the first-in-human trial initiated in Melbourne, Australia, in June 2023. The study progressed to the Multiple Ascending Dose stage in September 2023, with participants receiving once-daily dosing, followed by a food-effect study in November 2023.
SDC-1801 was selected as the lead clinical candidate from a novel compound series discovered and developed by Sareum through a rigorous candidate-selection process. In parallel, the company is evaluating additional dual TYK2/JAK1 inhibitors for their potential application in the treatment of selected cancers and as potential backup candidates to SDC-1801.
The anticipated launch of these emerging therapies are poised to transform the JAK inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the JAK inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about JAK inhibitors in development, visit @ JAK Inhibitor Clinical Trials
Recent Developments in the JAK Inhibitors Market
JAK Inhibitors Epidemiology Segmentation
The JAK inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets.
The JAK inhibitor target patient pool is segmented into:
JAK Inhibitors Report Metrics
Details
Study Period
2022–2036
JAK Inhibitors Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Alopecia Areata, Ulcerative Colitis, Crohn's Disease, Myelofibrosis, Polycythemia Vera, GvHD, Vitiligo, Systemic Lupus Erythematosus, Hidradenitis Suppurativa, and others
JAK Inhibitors Target Patient Pool Analysis
Total Eligible Patient Pool for JAK Inhibitors, Total Cases of Selected Indications for JAK Inhibitors, and Total Treated Cases in Selected Indications for JAK Inhibitors
Key JAK Inhibitors Companies
Incyte, Prelude Therapeutics, Biohaven, Aclaris Therapeutics, Highlightll Pharma, Sareum Holdings, Accro Bioscience, Fosun Pharma, Priovant Therapeutics, Pfizer, AbbVie, and others
Key JAK Inhibitors
Povorcitinib, PRT12396, BHV-8000, Modzatinib (ATI-2138), TLL-018, SDC-1801, AC-201/FXS5626, Brepocitinib, JAKAFI, RINVOQ, and others
Scope of the JAK Inhibitors Market Report
Discover JAK inhibitor news @ JAK Inhibitor Medications
Table of Contents
1
JAK Inhibitors Market Key Insights
2
JAK Inhibitors Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
JAK Inhibitor Market Overview at a Glance
6.1
Current and Emerging Therapies Analysis (By Phase, RoA, and Molecule Type)
6.2
Market Share (%) Distribution by Therapies in 2025 in the 7MM
6.3
Market Share (%) Distribution by Therapies in 2036 in the 7MM
6.4
Market Share (%) Distribution by Indications in 2025 in the 7MM
6.5
Market Share (%) Distribution by Indications in 2036 in the 7MM
7
Disease Background and Overview
7.1
Introduction
7.2
Clinical Significance
7.3
Diagnosis
7.4
Diagnostic Guidelines and Recommendations for JAK Inhibitors
8
Treatment
9
Epidemiology and Patient Population
10
Marketed Therapies of JAK Inhibitors
10.1
Marketed Competitive Landscape of JAK Inhibitors
10.2
Sotorasib (LUMAJAK/LUMYJAK): Amgen
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Clinical Development
10.2.4.1
Clinical Trial Information
10.2.5
Safety and Efficacy
10.2.6
Analyst Views
10.3
Adagrasib (KRAZATI): Bristol Myers Squibb
10.4
Avutometinib + Defactinib (AVMAPKI + FAKZYNJA Co-Pack): Verastem Oncology
11
Emerging Therapies of JAK Inhibitors
11.1
Key Emerging Competitive Landscape of JAK Inhibitors
11.2
Safety and Efficacy Data of Phase I/II Emerging Drugs
11.3
Safety and Efficacy Data of Phase I Emerging Drugs
11.4
Divarasib (RG6330): Roche/Chugai/Genentech
11.4.1
Product Description
11.4.2
Other Developmental Activities
11.4.3
Clinical Development
11.4.3.1
Clinical Trials Information
11.4.4
Safety and Efficacy
11.4.5
Analyst Views
11.5
Olomorasib (LY3537982): Eli Lilly and Company
11.6
MK-1084: Merck, Taiho, and Astex Pharmaceuticals
12
JAK Inhibitors Market: Seven Major Market Analysis
12.1
Key Findings
12.2
JAK Inhibitors Market Outlook
12.3
Conjoint Analysis
12.4
Key JAK Inhibitors Market Forecast Assumptions
12.5
Total Market Size of JAK Inhibitors by Country in the 7MM
12.6
Total Market Size of JAK Inhibitors by Indications in the 7MM
12.7
United States JAK Inhibitors Market Size
12.7.1
Total Market Size of JAK Inhibitors in the United States
12.7.2
Market Size of JAK Inhibitors by Therapies in the United States
12.8
EU4 and the UK JAK Inhibitors Market Size
12.9
Japan JAK Inhibitors Market Size
13
Unmet Needs
14
SWOT Analysis
15
KOL Views
16
JAK Inhibitors Market Access and Reimbursement
16.1
United States
16.2
EU4 and the UK
16.3
Japan
16.4
Market Access and Reimbursement of JAK Inhibitors
17
Bibliography
18
JAK Inhibitors Market Report Methodology
Related Reports
JAK Inhibitors Clinical Trial Analysis
JAK Inhibitors Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitor companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.
Atopic Dermatitis Market
Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies including Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, AbbVie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, among others.
Inflammatory Bowel Disease Market
Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IBD companies including Abivax, Merck, RedHill Biopharma, Teva Pharmaceuticals, Sanofi, Agomab, Ferring Pharmaceuticals, Johnson & Johnson, Eli Lilly, Athos Therapeutics, Spyre Therapeutics, Inc., Direct Biologics, LLC, Takeda, AbbVie, Tr1X, Inc., Xencor, Inc., and others.
Rheumatoid Arthritis Market
Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including Cyxone, Taiho Pharmaceutical, AstraZeneca, Eli Lilly and Company, Rise Therapeutics, TNF Pharmaceuticals, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
SOURCE DelveInsight Business Research, LLP